Chr. Hansen's lead on probiotic documentation emphasized with yet another study

Press release -

Chr. Hansen's lead on probiotic documentation emphasized with yet another study

New results from a recent study on Chr. Hansen’s flagship probiotic strains Bifidobacterium BB-12® and Lactobacillus rhamnosus LGG® further emphasize Chr. Hansen’s position as the supplier of the industry’s most documented probiotic portfolio.

Combining the intake of Bifidobacterium BB-12® and Lactobacillus rhamnosus GG® with dietary counseling can reduce the risk of diabetes during pregnancy; improve blood glucose control; and may promote child health, a Finnish study concludes.

The Finnish researcher team used a randomized, controlled trial of 256 pregnant women to investigate the effect of dietary counseling and probiotics on pregnant women and their newborns (British Journal of Nutrition, 2010 Jun;103 (12):1792-9. Epub 2010 Feb 4). The study which was initiated in 2002 has so far been documented in three different publications.

Abstracts of the three publications can be found on:
http://www.ncbi.nlm.nih.gov/pubmed/18154905
http://www.ncbi.nlm.nih.gov/pubmed/19017418
http://www.ncbi.nlm.nih.gov/pubmed/20128938

“This study is good news for vendors offering probiotic supplements to pregnant women and their infants,” says Chr. Hansen’s Sune Schmoelker, Commercial Development Director, Human Health & Nutrition, and continues: “The fact that the high daily dosage of 10 billion CFU (Colony Forming Units) was well tolerated by the test subjects makes BB-12® and LGG® attractive probiotic strains for products targeted at this consumer segment – in terms of efficacy as well as safety.”

Most characterized strain

BB-12® is very likely the most thoroughly characterized probiotic strain in the world. Recently this position was further established when researchers at Chr. Hansen revealed the complete genome sequence of BB-12® in the May 2010 issue of The Journal of Bacteriology.

“This study maps the complete genome sequence of BB-12®. It is a single circular chromosome of 1,942,198 base pairs with 1,642 predicted protein coding genes, four rRNA operons and 52 tRNA genes” as Eric Johansen, Associate Vice President, Chr. Hansen explains. “Knowledge of this sequence will lead to insight into the specific features which give this strain its probiotic properties. And hopefully this will also enable us to discover new properties of BB-12®,” he ends.

Best documentation

With the oldest study dating back to 1986, the benefits of Chr. Hansen’s probiotics have been documented for more than two decades. “Hundreds of studies have been published on both LGG® and BB-12®. Of these, approximately 300 are human studies. These two strains are thus the most well-documented probiotic strains on the market,” Sune Schmoelker concludes.

Topics

Chr. Hansen is a global bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. The products include cultures, enzymes, probiotics and natural colors, and all solutions are based on strong research and development competencies coupled with significant technology investments. Revenue in the 2013/14 financial year was EUR 756 million. The company holds a leading market position in all its divisions: Cultures & Enzymes, Health & Nutrition and Natural Colors. It has more than 2,500 dedicated employees in over 30 countries and main production facilities in Denmark, France, USA and Germany. Chr. Hansen was founded in 1874 and is listed on NASDAQ OMX Copenhagen.

Contacts

Helle Rexen

Helle Rexen

Press contact Media relations officer +45 20 74 28 40

About us

Chr. Hansen is a global, differentiated bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. At Chr. Hansen we are uniquely positioned to drive positive change through microbial solutions. We have worked for over 150 years to enable sustainable agriculture, better food and healthier living for more people around the world. Our microbial and fermentation technology platforms, including our broad and relevant collection of around 50,000 microbial strains, have game-changing potential. Matching customer needs and global trends we continue to unlock the power of good bacteria to respond to global challenges such as food waste, global health and the overuse of antibiotics and pesticides. As one of the world’s most sustainable companies, we touch the lives of more than 1 billion people every day. Driven by our legacy of innovation and curiosity to pioneer science, our purpose – To grow a better world. Naturally. – is at the heart of everything we do.

Chr. Hansen Holding A/S

Boege Allé 10-12
DK-2970 Hoersholm
Denmark

Chr. Hansen website
Investor Relations
Read more about Chr. Hansen
Enter your email address to follow Chr. Hansen Holding A/S

When you choose to create a user account and follow a newsroom your personal data will be used by us and the owner of the newsroom, for you to receive news and updates according to your subscription settings.

To learn more about this, please read our Privacy Policy, which applies to our use of your personal data, and our Privacy Policy for Contacts, which applies to the use of your personal data by the owner of the newsroom you follow.

Please note that our Terms of Use apply to all use of our services.

You can withdraw your consent at any time by unsubscribing or deleting your account.
Check your inbox

Email sent to __email__. Click the link there to follow Chr. Hansen Holding A/S.

Okay